Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

HKG: 6887

    • Home
    • HKG: 6887
Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) and Xtalpi Inc. (HKG: 2228) announced plans to...

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Fineline Cube Jan 15, 2026

Sunshine Lake Pharma Co., Ltd. (HKG: 6887) announced the launch of an AI-powered R&D platform focused...

Company Deals

Sunshine Lake Pharma Lists on HKEX via Introduction Method

Fineline Cube Jun 30, 2025

China-based Sunshine Lake Pharma Co., Ltd. (HKG: 6887) has successfully listed on the Main Board...

Recent updates

  • Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
  • Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
  • HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.